1. Scrip
  2. >>Therapy Areas

Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic

 
• By John Davis

With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.  

Peanuts
Just a handful of peanuts can induce an allergic reaction in susceptible individuals • Source: Shutterstock

Brisbane, California-based Aimmune Therapeutics Inc. already has the “foundations of a European commercial organization,” with an office in the UK and a legal entity in the Netherlands, president and CEO Jayson Dallas reported on March 25, 2019, as the company presented top-line data from the Phase III ARTEMIS study showing its candidate peanut allergy therapeutic, AR101, met its primary endpoint in the European trial.

The ARTEMIS study is the second Phase III study, after the company’s PALISADE study, to show AR101 has a statistically significant beneficial effect on how much peanut protein allergic patients can tolerate

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.